Patients dosed in Phase 1 safety and tolerability study of MDX2003, a novel T-cell engager designed to optimize killing of lymphomas Preclinical studies presented at 2025 American Society of ...

Metabolic tumor volume—a biomarker derived from PET imaging—can more accurately predict progression-free survival for large B ...

Researchers assessed whether using bispecific antibodies targeting CD20 and CD3 would reduce efficacy or increase toxicity in patients with relapsed or refractory non-Hodgkin B-cell lymphomas ...

Paediatric orbital tumours are rare, and primary orbital lymphomas are particularly uncommon, with an incidence of approximately 0.12 per 1000 000 children. Such lymphomas may present as orbital ...

Researchers found that loss of HDAC7 disrupted B-cell maturation in mouse models. Restoring HDAC7 suppressed tumor growth, ...

This Phase 1 dose-escalation trial will assess the safety, tolerability, pharmacokinetics and pharmacodynamic activity of ...

How Does Zynlonta Work for B-Cell Lymphoma? Zynlonta is an antibody drug conjugate (ADC), which is a type of targeted cancer medicine. ADCs work as smart bombs to find cancer cells in the body that ...

By using CRISPR/Cas9 to engineer cells from healthy donors, AVC-203 is designed to circumvent graft-versus-host disease and host-mediated rejection.

Key market opportunities for BCMA-targeted therapies include rising multiple myeloma cases, next-gen therapy approvals, ...